Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Teucrium Soybean Fund (SOYB) Price & Performance

Gilead Sciences, Inc.Trade
Teucrium Soybean FundTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Teucrium Soybean Fund — how do they compare? Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B), while Teucrium Soybean Fund trades at $24.82. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

GILDSOYB
Market Cap
$168.35B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$155.80$26.28
52-Week Low
$110.56$21.46
Enterprise Value
$191.42B
Dividend Yield
2.42%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Teucrium Soybean Fund

SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.

Read more on SOYB